Compare USNA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | PCRX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 1.1B |
| IPO Year | 1996 | 2010 |
| Metric | USNA | PCRX |
|---|---|---|
| Price | $15.03 | $25.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 203.7K | ★ 416.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $1,060,902,000.00 | $541,533,000.00 |
| Revenue This Year | $3.90 | $6.78 |
| Revenue Next Year | $6.21 | $8.54 |
| P/E Ratio | ★ N/A | $136.21 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $12.57 | $18.80 |
| 52 Week High | $31.15 | $27.66 |
| Indicator | USNA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 48.87 |
| Support Level | $12.57 | $24.61 |
| Resistance Level | $20.84 | $26.93 |
| Average True Range (ATR) | 0.63 | 0.66 |
| MACD | 0.41 | 0.04 |
| Stochastic Oscillator | 65.02 | 52.92 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.